UK's NICE issues short clinical treatment guideline for patients with type 2 diabetes

The National Institute for Health and Clinical Excellence (NICE), the advisory body that recommends which treatments should be covered by the  National Health Service outside Scotland, has issued guidance on the use  of newer agents for blood glucose control in adults with type 2  diabetes. The new, short clinical guideline is a partial update of last  year's suggested practices, titled Type 2 Diabetes (Update) and examines  several new and existing therapies for the management of blood glucose  levels in individuals with type 2 diabetes.

The NICE guidance recommends a number of new treatments to help manage  levels of blood glucose, positioning these among existing therapies for  type 2 diabetes. These include recommendations on the use of  long-acting insulin analogs, inhibitors of dipeptidylpeptidase-4  (DPP-4 inhibitors), glucagon-like peptide-1 (GLP-1) mimetics and  thiazolidinediones within their licensed recommendations.

Insulin (incl long-acting insulin analogs, insulin detemir, insulin  glargine)